Vibativ — HCPCS J3095 · Telavancin

About Vibativ (telavancin) FDA label verified Jul 2026

Telavancin is a semisynthetic lipoglycopeptide — a vancomycin derivative with a dual mechanism (inhibits cell-wall synthesis and disrupts the bacterial membrane) — active against Gram-positive organisms including MRSA. It is dosed once daily by weight, which in isolation sounds OPAT-friendly, but the clinical reality is the opposite: telavancin carries two FDA boxed warnings, requires frequent renal monitoring, and interferes with coagulation labs, so it sits at the salvage end of the MRSA-agent shelf rather than in routine outpatient use.

Vibativ is marketed by Cumberland Pharmaceuticals. From a billing standpoint the drug is unusually simple in one way and unusually error-prone in another. Simple: there is one permanent HCPCS code, J3095, at 10 mg per unit — no manufacturer-specific splits (unlike vancomycin J3373–J3376 or daptomycin J0877/J0872–J0874) and no biosimilars. Error-prone: telavancin now ships only in a 750 mg single-dose vial, and because dosing is weight-based, the typical dose does not line up to a whole number of 750 mg vials — producing a large, payable JW discard that has to be reported correctly.

The billing story therefore concentrates in three places: the JW/JZ vial math against a single 750 mg vial size, the boxed-warning documentation (renal function, pregnancy testing) that payers and post-payment reviewers expect on a high-risk drug, and honest indication framing — cSSSI is the everyday indication, while HABP/VABP is reserved by the label itself for when alternatives are unsuitable, and neither is a routine home-infusion scenario.

One code, one marketed vial — why that drives the waste math FDA NDC directory verified Jul 2026

Unlike vancomycin and daptomycin, telavancin has a single HCPCS with no manufacturer splits. The disambiguation that matters here is the vial supply: only the 750 mg single-dose vial is currently marketed.

There is no code trap for telavancin the way there is for oritavancin (Kimyrsa J2406 vs Orbactiv J2407) or daptomycin (J0878 vs J0877/J0872–J0874). Every telavancin claim is J3095. The thing that does trip billers is the vial supply. Telavancin currently ships only in 750 mg single-dose vials — the FDA National Drug Code directory lists the Cumberland 750 mg product (NDC 66220-315), and the legacy 250 mg presentation is no longer in the active directory. Cumberland’s own ordering page describes the product as a 750 mg powder for reconstitution.

Dose, units & the JW/JZ vial math FDA label verified Jul 2026

J3095 is billed at 1 unit = 10 mg on actual body weight. Because only the 750 mg vial is marketed, the JZ-vs-JW split depends entirely on whether the dose is an exact multiple of 750 mg.

FDA-labeled dosing & renal adjustment

Worked example A — 75 kg patient, 750 mg (exact vial, zero waste)

Worked example B — 80 kg patient, 800 mg (two vials, large JW discard)

NDC reference NDCs verified vs the FDA NDC directory, Jul 2026

Telavancin has one marketed vial size and one active labeler. Confirm the dispensed NDC before billing J3095.

Administration codes CPT verified Jul 2026

Telavancin is a therapeutic (non-chemotherapy) IV infusion given over 60 minutes once daily.

Full code guidance: 96365/96366 · all admin CPT references.

Home infusion — usually not the setting, but the service-code layer if it is

Telavancin is not a routine home-infusion drug (see site of care). If a program does deliver it at home, the drug J-code stays on the home-infusion pharmacy claim while the per-diem service code is billed separately by the home-infusion provider — the antibiotic S-code family (S9494 umbrella total per-diem, S9500 for every-24-hour dosing) for commercial/Medicaid, or Medicare’s Home Infusion Therapy G-codes (G0068/G0069/G0070). See the IV antibiotics reference for the full S-code/G-code table.

Modifiers CMS verified Jul 2026

JW / JZ — single-dose vial waste reporting

Per CMS’s July 2023 single-dose-container policy (CR 12056), every J3095 claim needs exactly one of JZ (no discard) or JW (discard). Telavancin ships only in a 750 mg single-dose vial, so the modifier always applies. Because weight-based doses rarely land on an exact multiple of 750 mg, JW is the common case:

Modifier 25 — same-day E/M

Append modifier 25 to the office/clinic E/M (99202–99215) when a significant, separately identifiable evaluation and management service is performed the same day as the infusion — common when the salvage decision to use telavancin (and the boxed-warning risk discussion) is documented at the same visit.

340B modifiers (JG, TB) & KX

For 340B-acquired telavancin at eligible covered entities, follow your MAC’s current 340B modifier policy (JG or TB as directed). Some payers require KX to attest that the salvage-use criteria (failure of or contraindication to preferred agents) are met — check the policy before submitting.

ICD-10-CM by indication FY2026 · verified Jul 2026

The diagnosis must support the FDA-labeled indication (MRSA cSSSI, or HABP/VABP when alternatives are unsuitable). Pair with the organism code where documented.

Site of care & safety monitoring — why this is a salvage, not routine-OPAT, drug Verified Jul 2026

Once-daily dosing makes telavancin look operationally OPAT-friendly, but that is where the resemblance to the OPAT workhorses ends. The boxed warnings, the required renal monitoring, and the coagulation-lab interference make it a specialist/salvage agent. Most HABP/VABP use is inpatient (often DRG-bundled); cSSSI salvage use in an infusion suite is uncommon and monitoring-intensive. This page frames it honestly: telavancin is not a routine outpatient parenteral antibiotic therapy choice, and CareCost’s own clinical data flags it as not appropriate for routine home use.

Claim form field mapping CMS verified Jul 2026

Outpatient telavancin is a CMS-1500 (837P) or UB-04 (837I) claim; inpatient HABP/VABP courses bundle into the DRG and are not separately Part B billable.

Payer policy snapshot Reviewed Jul 2026 · verify current policy

Coverage is real for the FDA-labeled indications, but step-therapy pressure is heavy: payers routinely require documented vancomycin (and often daptomycin) failure or contraindication before approving telavancin.

Step therapy is the dominant lever

Because telavancin sits behind vancomycin, daptomycin, linezolid, and the single-dose lipoglycopeptides, the friction is almost always step therapy plus the boxed-warning documentation, not indication coverage. Submit chart notes documenting the prior-therapy failure or contraindication that justified telavancin, along with the renal-monitoring and pregnancy-testing plan.

No drug-specific coverage article found

As of this review, no MAC lists telavancin on a Self-Administered Drug (SAD) exclusion list, and no drug-specific Local Coverage Determination (LCD) or coverage article was found. Coverage runs through the standard Medicare Part B drug framework.

Medicare reimbursement — J3095 reimbursement (2026) CMS payment limit verified Q2 2026

J3095 is paid off the CMS Part B payment limit (the ASP-based allowance that already includes the statutory 6% add-on). At the current payment limit a typical weight-based dose runs a few hundred dollars in allowed drug charges — and the JW discard on a non-750 mg dose is a meaningful share of it.

Coverage

There is no telavancin-specific NCD; coverage runs through the standard Medicare Part B drug framework for the FDA-approved indications. No SAD-list exclusion and no drug-specific LCD/article were identified as of this review.

Code history

• J3095 — permanent HCPCS, "Injection, telavancin, 10 mg." A single code for the product — no manufacturer-specific splits and no biosimilar codes.

Patient assistance Verified Jul 2026

Telavancin has an active commercial copay program and a currently-closed free-drug program — set patient expectations by insurance type before the infusion.

• Vibativ Co-Pay Program (Cumberland Pharmaceuticals) — commercial-insurance copay assistance. Most commercially insured patients pay $0 per therapy day; the program benefit is capped at $135 per therapy day with a maximum of $1,200 per calendar year. Not for patients with Medicare, Medicaid, or other federal/state coverage, and it cannot be redeemed at government-subsidized clinics. Enroll or verify at info.vibativ.com/co-pay-card or 877-683-6110. Verified active July 2026.
• Vibativ Patient Assistance Program (free drug) — the manufacturer’s free-drug program for qualifying uninsured/underinsured patients is currently closed (verified July 2026). Do not route patients to it as an active option; screen hospital charity care and 340B pathways instead.
• Government-insured patients — the Vibativ Co-Pay Program does not apply. Medicare Part B patients owe standard ~20% coinsurance on the Medicare payment-limit allowed amount. Independent infectious-disease foundation funds for this indication are uncommon — verify current open funds before relying on them.
• 340B — for eligible covered entities purchasing Vibativ under 340B, the discount accrues to the entity per the MAC's 340B modifier policy; it does not directly change the patient's coinsurance.

Common denials & how to fix them Reviewed Jul 2026

Frequently asked questions

What is the HCPCS J-code for Vibativ (telavancin)?

Vibativ is billed under HCPCS J3095 at 10 mg per unit, so a 750 mg dose is J3095 × 75. There is a single permanent code for telavancin — no manufacturer-specific split codes and no biosimilar codes, because telavancin is a single branded product (Cumberland Pharmaceuticals). Match the dispensed NDC to J3095 on the claim.

How do I bill Vibativ vial waste with JW and JZ?

Telavancin currently ships only in a 750 mg single-dose vial, so the vial math depends entirely on the weight-based dose. A 75 kg patient dosed at 10 mg/kg needs exactly 750 mg — one whole vial, zero discard — billed J3095 × 75 on a single line with modifier JZ. Any dose that is not an exact multiple of 750 mg forces an additional vial and a discard: an 80 kg patient needs 800 mg, drawn from two 750 mg vials (1,500 mg opened), leaving 700 mg discarded — bill J3095 × 80 on the administered line with no waste modifier, plus a separate J3095 line with JW × 70 for the discard. JW and JZ are mutually exclusive on the same drug and date of service, and JW units are payable at the Medicare payment limit (the ASP-based allowance that already includes the 6% add-on).

Why does Vibativ have boxed warnings, and is it a routine OPAT drug?

Telavancin carries two FDA boxed warnings: nephrotoxicity (including increased mortality versus vancomycin when used for HABP/VABP in patients with baseline CrCl ≤50 mL/min) and embryo-fetal toxicity (verify pregnancy status before use). Because of these warnings, the required frequent renal monitoring, and coagulation-test interference, telavancin is a specialist/salvage agent, not a routine OPAT choice. It is reserved for patients who have failed or cannot use vancomycin, daptomycin, linezolid, or the single-dose lipoglycopeptides.

What is the standard telavancin dose and how is it adjusted for kidney function?

The FDA-labeled dose is 10 mg/kg IV infused over 60 minutes once every 24 hours, on actual body weight. Renal adjustment by CrCl: 7.5 mg/kg q24h for 30–49 mL/min; 10 mg/kg q48h for 10–29 mL/min; not recommended below 10 mL/min or on hemodialysis. Because the marketed vial is 750 mg, each weight-based dose is rounded to whole 750 mg vials for supply, which drives the JW discard math.

Does Vibativ interfere with coagulation labs?

Yes. Telavancin artifactually elevates PT, INR, aPTT, and activated clotting time in samples drawn while drug is present — the label reports interference in samples collected 0 to 18 hours after a dose for once-daily administration. Per the label, draw coagulation samples as close as possible before the patient's next telavancin dose. Concomitant IV unfractionated heparin is contraindicated because telavancin makes aPTT-based heparin monitoring unreliable; a chromogenic factor Xa assay or an alternative anticoagulant can be considered instead.

Is there a copay program for Vibativ?

Yes. The Vibativ Co-Pay Program (Cumberland Pharmaceuticals) is commercial-insurance-only: most commercially insured patients pay $0 per therapy day, with a benefit cap of $135 per therapy day and a maximum of $1,200 per calendar year. It excludes Medicare, Medicaid, and other federal or state programs. The separate free-drug patient assistance program is currently closed. Verified July 2026.

Source documents

1. DailyMed — Vibativ (telavancin) prescribing information
   Current FDA label (Cumberland, label revised Nov 2023); boxed warnings, 10 mg/kg q24h dosing, renal adjustment, coagulation-test interference, IV heparin contraindication
2. CMS HCPCS Level II — J3095
   "Injection, telavancin, 10 mg"; single permanent code, no manufacturer-split or biosimilar codes
3. CMS — Medicare Part B Drug ASP Pricing File
   Quarterly Part B payment-limit pricing (ASP-based, includes the 6% add-on); J3095 = $7.032/10 mg (Q2 2026), live-bound on this page
4. CMS — JW/JZ modifier policy (CR 12056, eff. July 2023)
   Single-dose-container discard reporting; applies to telavancin's 750 mg single-dose vial
5. FDA National Drug Code Directory — telavancin NDCs
   Cumberland 750 mg vial (NDC 66220-315) is the only currently marketed presentation; legacy 250 mg NDC absent from the active directory (accessed Jul 2026)
6. Cumberland — Vibativ ordering page
   Describes Vibativ as a 750 mg powder for reconstitution; 750 mg vial only (accessed Jul 2026)
7. AMA CPT — therapeutic IV infusion codes (96365, 96366)
   Administration coding for the 60-minute infusion
8. CMS — ICD-10-CM (FY2026)
   L02.x/L03.x/L08.x cSSSI codes; J15.212 MRSA pneumonia; J95.851 VABP; B95.62 MRSA organism
9. Cumberland — Vibativ Co-Pay Program
   Commercial-only copay assistance ($0/therapy day; $135/therapy-day cap; $1,200/calendar-year max); free-drug patient assistance program currently closed; verified Jul 2026. Phone 877-683-6110
10. CMS Medicare Coverage Database
    Searched for telavancin-specific NCD/LCD/coverage article and SAD-list entries; none found as of this review

About this page

We maintain this page as a living reference for billers, coders, and revenue-cycle staff working with Vibativ claims in infectious disease, hospital medicine, and infusion-center practices. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes. The J3095 payment-limit figure is live-bound to the CareCost CMS Part B payment-limit layer, so the per-unit price reflects the current quarter automatically.

Found an error? Email hello@carecostestimate.com.

Refresh cadence

Reviewer

Change log

• Jul 14, 2026 — Initial publication. Vibativ (telavancin) billing reference: J3095 at 10 mg/unit with live ASP binding; the 750-mg-only marketed vial and its JW/JZ discard math (75 kg / 750 mg zero-waste JZ vs 80 kg / 800 mg two-vial JW example); 10 mg/kg q24h dosing with renal-interval adjustments; the nephrotoxicity and embryo-fetal-toxicity boxed warnings and the not-routine-OPAT framing; coagulation-test interference and IV-unfractionated-heparin contraindication; cSSSI/HABP-VABP ICD-10; and the commercial-only Vibativ Co-Pay Program alongside the closed free-drug patient assistance program.

Methodology

Every claim on this page is sourced inline. Dosing, indications, boxed warnings, and the coagulation interference are taken from the current FDA prescribing information; the marketed vial size is confirmed against the FDA NDC directory and Cumberland's ordering page; the payment-limit figure is read live from the CMS Part B payment-limit (ASP) pricing file; administration codes are from AMA CPT; and copay-program terms are read directly from Cumberland's current patient-support page. We do not paraphrase from billing-software vendor blogs, and we flag anything not yet SME-verified rather than assert it.